The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis
Open accessAbstract
The recently completed European trial of interferon beta-1b (IFNbeta-1b) in patients with secondary progressive multiple sclerosis (SP multiple sclerosis) has given an opportunity to assess the impact of treatment on cerebral atrophy using serial MRI. Unenhanced T(1)-weighted brain imaging was acquired in a subgroup of 95 patients from five of the European centres; imaging was performed at 6-month intervals from month 0 to month 36. A blinded observer measured cerebral volume on four contiguous 5 mm cerebral hemisphere slices at each time point, using an algorithm with a high level of reproducibility and automation. There was a significant and progressive reduction in cerebral volume in both placebo and treated groups, with a mean reduction of 3.9 and 2.9%, respectively, by month 36 (P = 0.34 between groups). Exploratory subgroup analyses indicated that patients without gadolinium (Gd) enhancement at the baseline had a greater reduction of cerebral volume in the placebo group (mean reduction at month 36: placebo 5.1%, IFNbeta-1b 1.8%, P < 0.05) whereas those with Gd-enhancing lesions showed a trend to greater reduction of cerebral volume if the patient was on IFNbeta-1b (placebo 2.6%, IFNbeta-1b 3.7%; P > 0.05). These results are consistent with ongoing tissue loss in both arms of this study of secondary progressive multiple sclerosis. This finding is concordant with previous observations that disease progression, although delayed, is not halted by IFNbeta. The different pattern seen in patients with and without baseline gadolinium enhancement suggests that part of the cerebral volume reduction observed in IFNbeta-treated patients may be due to the anti-inflammatory/antioedematous effect of the drug. Longer periods of observation and larger groups of patients may be needed to detect the effects of treatment on cerebral atrophy in this population of patients with advanced disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kappos, L. (1998) · The Lancet · doi:10.1016/s0140-6736(98)10039-9 · Cited by 936
Self-citation
Cited by
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
The clinico-radiological paradox in multiple sclerosis revisited
Barkhof, F. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00003 · Cited by 726
Self-citationGray matter atrophy in multiple sclerosis: A longitudinal study
Fisher, E., Lee, J., Nakamura, K., & Rudick, R. A. (2008) · Annals of Neurology · doi:10.1002/ana.21436 · Cited by 670
Miller, D. H. (2002) · Brain · doi:10.1093/brain/awf177 · Cited by 631
Self-citationColes, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Self-citationGray matter atrophy is related to long‐term disability in multiple sclerosis
Fisniku, L. K., Chard, D. T., Jackson, J. S., Anderson, V. M., Altmann, D. R., Miszkiel, K. A., Thompson, A. J., & Miller, D. H. (2008) · Annals of Neurology · doi:10.1002/ana.21423 · Cited by 500
Self-citationWill the real multiple sclerosis please stand up?
Stys, P. K., Zamponi, G. W., van Minnen, J., & Geurts, J. J. G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3275 · Cited by 475
The measurement and clinical relevance of brain atrophy in multiple sclerosis
Bermel, R. A., & Bakshi, R. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70349-0 · Cited by 456
Eight-year follow-up study of brain atrophy in patients with MS
Fisher, E., Rudick, R. A., Simon, J. H., Cutter, G., Baier, M., Lee, J. C., Miller, D., Weinstock-Guttman, B., Mass, M. K., Dougherty, D. S., et al. (2002) · Neurology · doi:10.1212/01.wnl.0000036271.49066.06 · Cited by 374
Self-citationBrain atrophy in clinically early relapsing–remitting multiple sclerosis
Chard, D. T., Griffin, C. M., Parker, G. J. M., Kapoor, R., Thompson, A. J., & Miller, D. H. (2002) · Brain · doi:10.1093/brain/awf025 · Cited by 366
Self-citationAssessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Self-citationDemyelination versus remyelination in progressive multiple sclerosis
Bramow, S., Frischer, J. M., Lassmann, H., Koch-Henriksen, N., Lucchinetti, C. F., Sørensen, P. S., & Laursen, H. (2010) · Brain · doi:10.1093/brain/awq250 · Cited by 319
Secondary progressive multiple sclerosis: current knowledge and future challenges
Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., & Filippi, M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70410-0 · Cited by 303
Self-citationClinical Relevance of Brain Volume Measures in Multiple Sclerosis
De Stefano, N., Airas, L., Grigoriadis, N., Mattle, H. P., O’Riordan, J., Oreja-Guevara, C., Sellebjerg, F., Stankoff, B., Walczak, A., Wiendl, H., et al. (2014) · CNS Drugs · doi:10.1007/s40263-014-0140-z · Cited by 301
MR Imaging of Multiple Sclerosis
Filippi, M., & Rocca, M. A. (2011) · Radiology · doi:10.1148/radiol.11101362 · Cited by 281
Self-citationInflammation, demyelination, and degeneration — Recent insights from MS pathology
Stadelmann, C., Wegner, C., & Brück, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.007 · Cited by 276
on behalf of the MAGNIMS study group, Sastre-Garriga, J., Pareto, D., Battaglini, M., Rocca, M. A., Ciccarelli, O., Enzinger, C., Wuerfel, J., Sormani, M. P., Barkhof, F., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0314-x · Cited by 273
Self-citationMechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis
Zivadinov, R., Reder, A. T., Filippi, M., Minagar, A., Stüve, O., Lassmann, H., Racke, M. K., Dwyer, M. G., Frohman, E. M., & Khan, O. (2008) · Neurology · doi:10.1212/01.wnl.0000316810.01120.05 · Cited by 260
Self-citationLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
Kappos, L., Traboulsee, A., Constantinescu, C., Erälinna, J. P., Forrestal, F., Jongen, P., Pollard, J., Sandberg-Wollheim, M., Sindic, C., Stubinski, B., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237994.95410.ce · Cited by 257
Self-citationLopes Pinheiro, M. A., Kooij, G., Mizee, M. R., Kamermans, A., Enzmann, G., Lyck, R., Schwaninger, M., Engelhardt, B., & de Vries, H. E. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.10.018 · Cited by 247
Interferon-β1bin multiple sclerosis
Buttmann, M., & Rieckmann, P. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.3.227 · Cited by 43
Cuprizone‐induced demyelination triggers a CD8‐pronounced T cell recruitment
Kaddatz, H., Joost, S., Nedelcu, J., Chrzanowski, U., Schmitz, C., Gingele, S., Gudi, V., Stangel, M., Zhan, J., Santrau, E., et al. (2021) · Glia · doi:10.1002/glia.23937 · Cited by 51
“Most importantly, current immunomodulatory or anti-inflammatory treatments have little or no beneficial effect in the progressive stage of the disease (Coles et al., 1999; La Mantia et al., 2012; Lorscheider et al., 2017; Miller et al., 1999; Molyneux et al., 2000).”
Background
Metadata
- Authors
- Molyneux, P. D., Kappos, L., Polman, C., Pozzilli, C., Barkhof, F., Filippi, M., Yousry, T., Hahn, D., Wagner, K., Ghazi, M., Beckmann, K., Dahlke, F., Losseff, N., Barker, G. J., Thompson, A. J., & Miller, D. H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-11
- Volume
- 123
- Issue
- 11
- Pages
- 2256-2263
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2099467824
- Cited by
- 241
- References
- 1
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.